S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
Log in
NASDAQ:PROF

Profound Medical Stock Forecast, Price & News

$27.06
+0.37 (+1.39 %)
(As of 01/26/2021 01:08 PM ET)
Add
Compare
Today's Range
$26.64
Now: $27.06
$27.24
50-Day Range
$20.44
MA: $22.63
$26.37
52-Week Range
$6.53
Now: $27.06
$27.20
Volume2,224 shs
Average Volume83,208 shs
Market Capitalization$531.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. has a co-development agreement with GE Healthcare to expand provider access to TULSA-PRO. Profound Medical Corp. is headquartered in Mississauga, Canada.

MarketRank

Overall MarketRank

1.09 out of 5 stars

Medical Sector

749th out of 1,922 stocks

Surgical & Medical Instruments Industry

75th out of 168 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PROF
CUSIPN/A
CIKN/A
Phone647 476 1350
Employees75
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.17 million
Book Value$0.92 per share

Profitability

Net Income$-15,220,000.00
Net Margins-275.12%

Miscellaneous

Market Cap$531.08 million
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$27.06
+0.37 (+1.39 %)
(As of 01/26/2021 01:08 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PROF News and Ratings via Email

Sign-up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Profound Medical (NASDAQ:PROF) Frequently Asked Questions

How has Profound Medical's stock been impacted by Coronavirus?

Profound Medical's stock was trading at $10.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PROF shares have increased by 146.2% and is now trading at $27.06.
View which stocks have been most impacted by COVID-19
.

Is Profound Medical a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last twelve months. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Profound Medical stock.
View analyst ratings for Profound Medical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Profound Medical?

Wall Street analysts have given Profound Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Profound Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Profound Medical's next earnings date?

Profound Medical is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Profound Medical
.

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) issued its earnings results on Thursday, November, 5th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.09. The business earned $2.24 million during the quarter, compared to analyst estimates of $2.30 million. Profound Medical had a negative trailing twelve-month return on equity of 33.69% and a negative net margin of 275.12%.
View Profound Medical's earnings history
.

What guidance has Profound Medical issued on next quarter's earnings?

Profound Medical updated its fourth quarter 2020 After-Hours earnings guidance on Tuesday, January, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.7-3.7 million.

What price target have analysts set for PROF?

6 Wall Street analysts have issued 12-month price objectives for Profound Medical's stock. Their forecasts range from $15.00 to $43.00. On average, they anticipate Profound Medical's share price to reach $29.56 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Profound Medical
or view Wall Street analyst' top-rated stocks.

Who are some of Profound Medical's key competitors?

Who are Profound Medical's key executives?

Profound Medical's management team includes the following people:
  • Dr. Arun Swarup Menawat, Chairman & CEO (Age 66)
  • Mr. Aaron Davidson M.B.A., MBA, CFO & Sr. VP of Corp. Devel. (Age 53)
  • Dr. Mathieu Burtnyk, Vice-Pres of Clinical Affairs
  • Mr. Stephen Kilmer, Investor Relations
  • Mr. Jacques F. Cornet, VP of Marketing & Bus. Devel. (Age 65)
  • Mr. Michael Mydra, VP & Head of Global Market Access

What is Profound Medical's stock symbol?

Profound Medical trades on the NASDAQ under the ticker symbol "PROF."

How do I buy shares of Profound Medical?

Shares of PROF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Profound Medical's stock price today?

One share of PROF stock can currently be purchased for approximately $27.06.

How big of a company is Profound Medical?

Profound Medical has a market capitalization of $531.08 million and generates $4.17 million in revenue each year. The company earns $-15,220,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Profound Medical employs 75 workers across the globe.

What is Profound Medical's official website?

The official website for Profound Medical is www.profoundmedical.com.

How can I contact Profound Medical?

Profound Medical's mailing address is 2400 SKYMARK AVENUE UNIT 6, MISSISSAUGA A6, L4W 5K5. The company can be reached via phone at 647 476 1350 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.